✦ LIBER ✦

P.241 Treatment outcomes in patients with hepatitis C virus genotype 1a and 1b and persistently ‘normal’ alanine aminotransferase (ALT) levels receiving peginterferon alpha-2a (40KD) plus ribavirin

✍ Scribed by S. Zeuzem; P. Marcellin; P. Pockros; N. Gitlin; P. Farci; M. Shiffman; J. Zarski; E. Gane; M. Diago

Book ID: 117770460
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 145 KB
Volume: 36
Category: Article
ISSN: 1386-6532
DOI: 10.1016/s1386-6532(06)80421-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predicting efficacy and safety outcomes

Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α-2a (40KD) plus ribavirin

✍ Eric Snoeck; Stephanos J. Hadziyannis; Claudio Puoti; Mark G. Swain; Thomas Berg 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB

Peginterferon alpha-2a and ribavirin in

Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels

✍ Calleja, José-Luis; García-Samaniego, Javier; Ruiz-Antorán, Belén; Trapero, Marí 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB

503 Early prediction of sustained virolo

503 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels

✍ P.J. Pockros; M. Diago; E. Gane; K.R. Reddy; D. Prati; M.L. Shiffman; P. Farci; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 65 KB

622 Efficacy and safety of peginterferon

622 Efficacy and safety of peginterferon alpha-2a (40KD) [PEG] plus ribavirin [RBV] 1000/1200 mg/d in genotype 1 patients with chronic hepatitis C and ‘normal’ ALT levels

✍ E. Zehnter; S. Mauss; C. John; R. Heyne; B. Möller; T. Lutz; B. Bokemeyer; R. Ki 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Impact of IL28B on treatment outcome in

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin

✍ Thomas-Matthias Scherzer; Albert Friedrich Stättermayer; Michael Strasser; Herma 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 502 KB

The IL28B genotype is the most important pretreatment predictor of treatment outcome in patients with chronic hepatitis C. The impact of the rs12979860 genotype on relapse was retrospectively evaluated in genotype 1/4 patients who received response-guided therapy with peginterferon alpha-2a 180 μg/w

522 Combination therapy with peginterfer

522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR)

✍ O. Weiland; M.W. Fried; S.J. Hadziyannis; G.R. Foster; D. Messinger; K. Freivoge 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB